VWA5A Antikörper

Produktnummer ABIN7240895

Produktdetails anti-VWA5A Antikörper

Target: VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VWA5A Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktmerkmale: Polyclonal Antibody

Aufreinigung: Affinity purification

Immunogen: Recombinant protein of human VWA5A

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:500-1:2000, IHC 1:100-1:300

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Avoid freeze / thaw cycles.

Details zu VWA5A

Target: VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))

Andere Bezeichnung: VWA5A (VWA5A Produkte)

Synonyme: VWA5A antikoerper, LOH11CR2A antikoerper, MGC68953 antikoerper, loh11cr2a antikoerper, BCSC-1 antikoerper, BCSC1 antikoerper, 5830475I06Rik antikoerper, AW552491 antikoerper, E130119J22 antikoerper, Loh11cr2a antikoerper, masa-1 antikoerper, loss of heterozygosity, 11, chromosomal region 2, gene A antikoerper, von Willebrand factor A domain containing 5A antikoerper, von Willebrand factor A domain containing 5A S homeolog antikoerper, LOH11CR2A antikoerper, VWA5A antikoerper, vwa5a.S antikoerper, vwa5a antikoerper, Vwa5a antikoerper

Hintergrund: VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80 % of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.

Molekulargewicht: 86 kDa

UniProt: O00534